BioMarin Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	348.9	426.86	167.65	141.56	-64.08
Depreciation & Amortization	72.16	96.43	104.39	101.97	108.04
Other Amortization	7.4	-	-	-	-
Loss (Gain) From Sale of Assets	-	-10	-	-108	-
Asset Writedown & Restructuring Costs	345.98	19.89	38.61	-	-
Loss (Gain) From Sale of Investments	-4.8	-8.35	-9.23	3.04	5.16
Stock-Based Compensation	181.41	201.57	207.1	196.31	197.26
Other Operating Activities	170.61	62.84	-12.71	-62.6	-7.88
Change in Accounts Receivable	-228.05	-57.91	-190.44	-82.03	65.57
Change in Inventory	-116.93	-63.53	-157.06	-68.26	-35.06
Change in Accounts Payable	66.14	-32.24	68.85	59.02	15.69
Change in Other Net Operating Assets	-14.81	-62.72	-57.9	-5.1	19.83
Operating Cash Flow	827.99	572.84	159.26	175.9	304.54
Operating Cash Flow Growth	44.54%	259.69%	-9.46%	-42.24%	256.75%
Capital Expenditures	-103.04	-85.42	-96.69	-120.96	-95.58
Cash Acquisitions	-285.19	-	-	-	-
Sale (Purchase) of Intangibles	-7.94	-1.99	-10.92	92.74	-23.65
Investment in Securities	-18.07	222.77	-3.63	8.19	-246.09
Other Investing Activities	-	1.14	-	-	-0.99
Investing Cash Flow	-414.24	136.49	-111.24	-20.03	-366.31
Long-Term Debt Repaid	-	-494.99	-	-	-3.04
Net Debt Issued (Repaid)	-	-494.99	-	-	-3.04
Issuance of Common Stock	14.46	49.28	69.35	69.33	49.19
Repurchase of Common Stock	-55.97	-77.56	-76.32	-54.28	-45.81
Other Financing Activities	-0.89	-3.18	-11.76	-33.7	-0.4
Financing Cash Flow	-42.39	-526.45	-18.73	-18.65	-0.05
Foreign Exchange Rate Adjustments	-2.52	4.83	1.31	0.03	-0.06
Net Cash Flow	368.84	187.72	30.6	137.26	-61.88
Free Cash Flow	724.96	487.42	62.57	54.94	208.96
Free Cash Flow Growth	48.73%	679.02%	13.88%	-73.71%	-
Free Cash Flow Margin	22.50%	17.08%	2.59%	2.62%	11.32%
Free Cash Flow Per Share	3.67	2.48	0.33	0.29	1.14
Cash Interest Paid	7.25	10.36	10.3	10.28	10.4
Cash Income Tax Paid	96.21	57.27	73.31	54.37	18.15
Levered Free Cash Flow	402.66	212.05	-148.78	137.32	201.61
Unlevered Free Cash Flow	409.47	219.97	-137.94	147.3	211.19
Change in Working Capital	-293.66	-216.4	-336.54	-96.38	66.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.